Yes, THC (delta-9-tetrahydrocannabinol) is a cannabinoid. It is, in fact, the primary cannabinoid found in the cannabis plant and the one most responsible for the “high” associated with marijuana use. THC belongs to a specific subclass called phytocannabinoids, meaning it’s naturally produced by a plant rather than made in a lab or generated by the human body.
What Cannabinoids Are
Cannabinoids are a broad family of chemical compounds that interact with a specific network of receptors throughout your body called the endocannabinoid system. They fall into three categories: phytocannabinoids (produced by the cannabis plant), endocannabinoids (produced naturally by your own body), and synthetic cannabinoids (manufactured in a laboratory).
The cannabis plant alone contains more than 550 chemical compounds, with over 100 of them classified as phytocannabinoids. THC and CBD are the two most abundant and well-studied of these, but they share space with dozens of minor cannabinoids like CBN (cannabinol), CBG (cannabigerol), and THCV (tetrahydrocannabivarin). CBN holds a notable distinction as the first phytocannabinoid ever isolated from cannabis, back in 1896.
How THC Works in the Body
Your body has its own cannabinoid-like molecules called endocannabinoids. These are lipid-based signaling molecules derived from fatty acids in cell membranes, and they help regulate everything from mood and appetite to pain and memory. THC produces its effects by mimicking these natural molecules and binding to the same receptors they use, particularly a receptor called CB1.
CB1 receptors are concentrated in the brain and eyes, with lower densities throughout the rest of the body. When THC latches onto a CB1 receptor, it partially activates it, triggering a chain of events inside the cell that ultimately reduces the release of certain chemical messengers between neurons. This disruption of normal signaling is what produces THC’s characteristic psychoactive effects: altered perception, euphoria, relaxation, and changes in memory and coordination.
THC is classified as a “partial agonist,” which means it activates CB1 receptors but not to their full capacity. It can shift between two different binding positions within the receptor, and only one of those positions triggers the conformational change that fully activates the cell’s internal signaling pathway. This partial activation is why THC produces a high but has a ceiling to its effects at a given dose.
Why THC Gets You High and CBD Doesn’t
THC and CBD come from the same plant and have remarkably similar chemical structures, yet they behave very differently in the body. The critical distinction is how each one interacts with CB1 receptors in the brain.
THC binds directly to the main binding site on CB1 receptors and partially activates them. CBD does not. Instead, CBD attaches to a different spot on the receptor and acts as a negative allosteric modulator, essentially changing the receptor’s shape so that other molecules (including THC itself) have a harder time activating it. In practical terms, CBD can actually dampen some of THC’s effects by making CB1 receptors less responsive.
CBD was long considered completely non-psychoactive, but that’s an oversimplification. At typical doses, people report feeling nothing from CBD alone. However, higher and lower doses have been shown to influence behavior and mood through different pathways, including receptors involved in anxiety and pain signaling. The more accurate way to think about it: CBD is not intoxicating, but it is psychoactive in subtler ways.
THC’s Role Among Minor Cannabinoids
While THC dominates the conversation, many of the 100-plus cannabinoids in cannabis are getting more attention. THCV, for instance, shares a similar structure with THC and binds to both CB1 and CB2 receptors, though it’s found in much smaller quantities and its exact pharmacological profile is still being worked out. Breeders are actively developing cannabis strains with higher THCV concentrations. CBDV, another minor cannabinoid, has shown effects similar to THC in some animal studies (particularly for nausea) but without the intoxicating properties.
These minor cannabinoids generally appear in very small amounts compared to THC and CBD. Their individual effects are less well understood, but they contribute to the overall chemical profile of any given cannabis product.
THC in Medicine
THC’s status as a cannabinoid has direct medical applications. The FDA has approved synthetic versions of THC for specific conditions. Dronabinol (sold as Marinol and Syndros) is a lab-made form of delta-9-THC approved to treat nausea from cancer chemotherapy and appetite loss in AIDS patients. Nabilone (sold as Cesamet) has a chemical structure similar to THC and is also approved for chemotherapy-related nausea.
These medications work through the same CB1 and CB2 receptor pathways as plant-derived THC. The synthetic route gives pharmaceutical manufacturers precise control over dosing and purity, which is why these products were able to clear the FDA’s approval process while whole-plant cannabis has not.
The Legal Line: 0.3% THC
Because THC is the cannabinoid responsible for intoxication, it’s the molecule that defines the legal boundary between hemp and marijuana in the United States. Under the 2018 Farm Bill, cannabis plants containing 0.3% or less THC by dry weight are classified as hemp and are federally legal. Any plant exceeding that threshold is considered marijuana and remains a Schedule I controlled substance under federal law.
This 0.3% cutoff applies specifically to delta-9-THC. It means that other cannabinoids like CBD, CBG, and CBN can be present in much higher concentrations and the plant still qualifies as legal hemp, as long as the THC stays below that line. The threshold has been criticized as somewhat arbitrary, but it remains the standard that governs the multibillion-dollar hemp industry.